Oslo, 18 January 2021: Reference is made to Navamedic ASA's ("Navamedic" or the
"Company") stock exchange announcement published on 4 January 2021 regarding the
board of director's resolution to increase the Company's share capital in
connection with the settlement of tranche 1 of the purchase price by issuing
consideration shares for the acquisition of marketing authorisations for a
series of antibiotics for hospital use in the Nordic region from ACS Dobfar and
InfoRLife. 

The share capital increase pertaining to the 1,053,775 consideration shares has
now been registered with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The new share capital of the Company is 12,095,788.40,
divided into 16,345,660 shares, each with a par value of NOK 0.74.

Following the registration of the new shares in the Norwegian Central Securities
Depository (the VPS), which is expected to take place today, the new shares will
be delivered to the subscriber and listed on the Oslo Stock Exchange.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to the
issuer rules for Oslo Børs.